Neurol. praxi. 2018;19(4):267-270 | DOI: 10.36290/neu.2018.104

Multiple sclerosis: treatment, monitoring, activity and disability

MUDr. Zbyšek Pavelek, doc. MUDr. Martin Vališ, Ph.D.
Neurologická klinika LF a FN Hradec Králové

Multiple sclerosis is a chronic inflammatory autoimmune disease which affect central nervous system. Treatment initiation ofearly multiple sclerosis may postpone thie development of disease progression and disablement. Goal of MS treatment is statewithout cninical and sublinical markers of diseasety aktivity, state known as NEDA (No Evidence of Disease Activity). This work isconcerned with treatment of MS, monitoring and predictors of treatment.

Keywords: multiple sclerosis, disability, magnetic resonance, biomarker

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelek Z, Vališ M. Multiple sclerosis: treatment, monitoring, activity and disability. Neurol. praxi. 2018;19(4):267-270. doi: 10.36290/neu.2018.104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ad?r HJ, Losseff N, Valk J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis, Brain. 1997; 120(Pt 11): 2059-2069. Go to original source...
    2. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E Lauda F, Kapfer T, Jesse S, Lehmensiek V, Ludolph AC, Otto M, Tumani H. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010; 5(8): e11986. Go to original source... Go to PubMed...
    3. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014; 83(11): 1022-1024. Go to original source... Go to PubMed...
    4. Calabrese M, Seppi D, Romualdi C, Rinaldi F, Alesio S, Perini P, Gallo P. Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population. AJNR Am J Neuroradiol 2012; 33: 1507-1511, 10.3174/ajnr.A3011. Go to original source...
    5. Comabella M, Fernandez M, Martin R, Rivera-Vallve S, Borras E, Chiva C, Borrás E, Chiva C, Juli? E, Rovira A, Cantó E, Alvarez-Cerme?o JC, Villar LM, Tintoré M, Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133(4): 1082- 1093. Go to original source...
    6. Cree BAC, Kappos L, Freedman MS, Cohen JA, Sprenger T, Ritter S, Tomic D, Piani Weber D. Long-term effects of fingolimod on NEDA by year of treatment. Poster presented at: 31st ECTRIMS Annual Congress; October 7-0, 2015; Barcelona, Spain. Poster Session 1; P627.
    7. Cree B, Vollmer TL. Clinically isolated syndrome evaluation, risk stratification and treatment decision. Adv Stud Med 2008; 8(8): 257-265.
    8. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782. Go to original source...
    9. Garcea O, Villa A, Cáceres F, Adoni T, Alegría M, Barbosa Thomaz R, Buzo R, Llamas López L, Rivera Kindel M: Early treatment of multiple sclerosis: a Latin American experts meeting, Mult Scler. 2009; 15(Suppl. 3): S1-S12. Go to original source... Go to PubMed...
    10. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10): 1175-1182. Go to original source... Go to PubMed...
    11. Grassiot B, Desgranges B, Eustace F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol 2009; 256: 1397-1412. Go to original source... Go to PubMed...
    12. Giovannoni G, Tomic D, Bright JR, Havrdová E. "No evident disease activity": the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017; 23(9): 1179-1187. Go to original source... Go to PubMed...
    13. Lu G, Beadnall HN, Barton J, Hardy TA, Wang C, Barnett MH. The evolution of "No Evidence of Disease Activity" in multiple sclerosis. Mult Scler Relat Disord. 2018; 20: 231-238. Go to original source... Go to PubMed...
    14. Maasaki N, Miyazaki Y. Radiologically isolated syndrome and clinically isolated syndrome. Clin Exp Neuroimmunol. 2017; 8(Suppl. 1): 24-32. Go to original source...
    15. Miller DH and Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6(10): 903-912. Go to original source...
    16. Miller JR. The importace of early diagnosis of multiple sclerosis. J Manag Care Pharm. 2004; 10(3 Suppl B): S4-11.
    17. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome, Neurology 2009; 72(9): 800-805. Go to original source... Go to PubMed...
    18. Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D. Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol 2011; 258: 2113-2127. Go to original source... Go to PubMed...
    19. Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk, DM. NEDA treatment target? No evident disease activity as an actionable outcome in practice. J Neurol Sci. 2017; 383: 31-34. Go to original source...
    20. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol. 2009; 16(11): 1202-1209. Go to original source...
    21. Prosperini L, Mancinelli CR, De Giglio L, De Angelis F, Barletta V, Pozzilli C. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler. 2014; 20(5): 566-576. Go to original source... Go to PubMed...
    22. Salzer J, Svenningsson A, Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16(3): 287- 292. Go to original source... Go to PubMed...
    23. Scalfari A, Neuhaus A, Degenhardt A, Rice G, Muraro P, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010; 133: 1914-1929. Go to original source... Go to PubMed...
    24. Sellebjerg F, Börnsen L, Ammitzb?ll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg S?rensen P, Romme Christensen J. Defining active progressive multiple sclerosis. Mult Scler. 2017; 23(13): 1727-1735. Go to original source... Go to PubMed...
    25. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of interferon beta and progression of disability in patients with relapsing - remitting multiple sclerosis. JAMA 2012; 308(3): 247- 256. Go to original source...
    26. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-173. Go to original source...
    27. Wattjes MP, Rovira ?, Miller D Yousry TA, Sormani MP, de Stefano MP, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik Barkhof, Xavier Montalban; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11(10): 597-606. Go to original source...
    28. Yamout B, Al Khawajah M. Radiologically isolated syndrome and multiple sclerosis. Mult Scler Relat Disord. 2017; 17: 234-237. Go to original source... Go to PubMed...
    29. Zetterberg H, Teunissen C. Fluid biomarkers for disease activity in multiple sclerosis. Mult Scler. 2017; 23(13): 1660-1661. Go to original source... Go to PubMed...
    30. Zhang Y, Metz LM, Yong VW, Mitchell JR. 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study. J. Neurol. Sci., 2010; 297: 76-81. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.